Kymera Therapeutics, Inc. (KYMR)
121.05
+1.25
(+1.04%)
USD |
NASDAQ |
Aug 24, 16:00
121.01
-0.04
(-0.03%)
After-Hours: 20:00
Kymera Therapeutics Profit Margin (Quarterly) : -94.17% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -94.17% |
| March 31, 2026 | -201.5% |
| December 31, 2025 | -3.03K% |
| September 30, 2025 | -2.97K% |
| June 30, 2025 | -667.6% |
| March 31, 2025 | -296.7% |
| December 31, 2024 | -956.9% |
| September 30, 2024 | -1.67K% |
| June 30, 2024 | -164.0% |
| March 31, 2024 | -472.0% |
| December 31, 2023 | -30.01% |
| September 30, 2023 | -1.12K% |
| June 30, 2023 | -235.0% |
| March 31, 2023 | -432.4% |
| Date | Value |
|---|---|
| December 31, 2022 | -216.0% |
| September 30, 2022 | -450.2% |
| June 30, 2022 | -349.6% |
| March 31, 2022 | -381.3% |
| December 31, 2021 | -221.9% |
| September 30, 2021 | -140.5% |
| June 30, 2021 | -133.2% |
| March 31, 2021 | -69.91% |
| December 31, 2020 | -99.22% |
| September 30, 2020 | -54.95% |
| June 30, 2020 | -425.5% |
| March 31, 2020 | -318.9% |
| December 31, 2019 | -628.1% |
| September 30, 2019 | -1.20K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -22.88% |
| Return on Assets | -20.55% |
| Return on Invested Capital | -21.53% |
| Gross Profit Margin (Quarterly) | 96.88% |
| Operating Margin (Quarterly) | -116.3% |
| Return on Net Operating Assets | -304.1% |